EICHORCondition: Major Depressive Disorder · Sponsor: Definium Therapeutics US, Inc.
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Emerge
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Preferred Research Partners, Inc | Little Rock, Arkansas, United States | — |
| Kadima Neuropsychiatry Institute | La Jolla, California, United States | — |
| Psychedelic Science Institute | Santa Monica, California, United States | — |
| Mountain View Clinical Research, Inc | Denver, Colorado, United States | — |
| Clinical Neuroscience Solutions, Inc - Jacksonville | Jacksonville, Florida, United States | — |
| Clinical Neuroscience Solutions, Inc - Orlando | Orlando, Florida, United States | — |
| Charter Research | Orlando, Florida, United States | — |
| Uptown Research Institute (URI), LLC | Chicago, Illinois, United States | — |
| Sheppard Pratt | Baltimore, Maryland, United States | — |
| Adams Clinical Boston | Boston, Massachusetts, United States | — |
| Adams Clinical | Watertown, Massachusetts, United States | — |
| University of Missouri | Columbia, Missouri, United States | — |
+ 10 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06941844